Table 3.
Quality-of-Life Outcomes, Proton Pump Inhibitor Use, and Satisfaction by Procedure Type for Each of the Follow-Up Study Cohorts
| 1 year | 3 years | 5 years | Trend analysis P value | |
|---|---|---|---|---|
| GERD-HRQL (mean ± SD) | ||||
| Toupet | 2.45 ± 4.08 | 3.57 ± 6.16 | 5.60 ± 5.83 | .07 |
| Nissen | 3.48 ± 5.29 | 2.42 ± 6.10 | 2.79 ± 6.44 | .69 |
| Between-procedure P value | .46 | .31 | .11 | |
| GCSI (mean ± SD) | ||||
| Toupet | 5.03 ± 6.60 | 7.70 ± 8.54 | 4.90 ± 4.48 | .37 |
| Nissen | 5.30 ± 4.91 | 5.50 ± 6.49 | 5.94 ± 7.51 | .62 |
| Between-procedure P value | .41 | .48 | .87 | |
| Eckardt (mean ± SD) | ||||
| Toupet | 1.61 ± 1.98 | 1.55 ± 1.63 | 1.30 ± 0.95 | .88 |
| Nissen | 2.35 ± 1.58 | 1.71 ± 1.76 | 1.45 ± 1.68 | .08 |
| Between-procedure P value | .03 | .75 | .74 | |
| PPI Use (%) | ||||
| Toupet | 15.8 | 59.6 | 70.0 | <.001 |
| Nissen | 27.3 | 41.7 | 37.7 | .48 |
| Between-procedure P value | .28 | .15 | .09 | |
| Satisfaction (%) | ||||
| Toupet | 86.8 | 74.5 | 70.0 | .13 |
| Nissen | 87.0 | 79.2 | 77.4 | .36 |
| Between-procedure P value | 1.00 | .77 | .67 | |
GCSI, Gastroparesis Cardinal Symptom Index; GERD-HRQL, gastroesophageal reflux disease healthcare-related quality of life; PPI, proton pump inhibitor.